in the absence of a submission from the holder of the marketing authorisation:
blinatumomab (Blincyto®) is not recommended for use within NHSScotland.
Indication under review: As monotherapy for the treatment of adults with CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL).
Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice619KB (PDF)
Medicine details
- Medicine name:
- blinatumomab (Blincyto®)
- SMC ID:
- SMC2468
- Indication:
As monotherapy for the treatment of adults with CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.
- Pharmaceutical company
- Amgen Ltd
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 07 March 2022